XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
Net product revenue | $ | 7,796.5 |  |  | $ | 6,238.2 |  |  |  |  |
Collaboration and other revenue | 971.5 |  |  | 721.8 |  |  |  |  |
Revenue | $ | 8,768.0 |  |  | $ | 6,960.0 |  |  |  |  |
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended March 31, 2024 and 2023:
| Three Months Ended March 31,
| 2024 |  | 2023
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Diabetes and obesity: |  |  |  |  |  |  |
Mounjaro® | $ | 1,520.4 |  | $ | 286.2 |  | $ | 1,806.5 |  |  | $ | 536.4 |  | $ | 32.0 |  | $ | 568.5 |
Trulicity® | 1,081.9 |  | 374.4 |  | 1,456.3 |  |  | 1,547.4 |  | 429.7 |  | 1,977.1 |
Jardiance(1) | 368.2 |  | 318.3 |  | 686.5 |  |  | 329.4 |  | 248.1 |  | 577.5 |
Humalog® (2) | 338.3 |  | 200.4 |  | 538.7 |  |  | 271.6 |  | 189.3 |  | 460.9 |
Zepbound® | 517.4 |  | — |  | 517.4 |  |  | — |  | — |  | — |
Humulin® | 153.1 |  | 53.1 |  | 206.2 |  |  | 198.8 |  | 53.2 |  | 252.0 |
Basaglar® (3) | 83.2 |  | 74.3 |  | 157.6 |  |  | 135.4 |  | 73.9 |  | 209.3 |
Other diabetes and obesity | 27.5 |  | 96.3 |  | 123.8 |  |  | 56.0 |  | 89.2 |  | 145.1 |
Total diabetes and obesity | 4,090.0 |  | 1,403.0 |  | 5,493.0 |  |  | 3,075.0 |  | 1,115.4 |  | 4,190.4 |
Oncology: |  |  |  |  |  |  |
Verzenio® | 638.2 |  | 412.1 |  | 1,050.3 |  |  | 461.1 |  | 289.8 |  | 750.9 |
Cyramza® | 107.2 |  | 122.6 |  | 229.9 |  |  | 100.6 |  | 136.1 |  | 236.8 |
Erbitux® | 132.1 |  | 12.5 |  | 144.6 |  |  | 118.8 |  | 11.1 |  | 129.9 |
Tyvyt® | — |  | 116.7 |  | 116.7 |  |  | — |  | 61.0 |  | 61.0 |
Other oncology | 120.8 |  | 147.8 |  | 268.5 |  |  | 72.9 |  | 104.6 |  | 177.4 |
Total oncology | 998.3 |  | 811.7 |  | 1,810.0 |  |  | 753.4 |  | 602.6 |  | 1,356.0 |
Immunology: |  |  |  |  |  |  |
Taltz® | 347.1 |  | 257.0 |  | 604.1 |  |  | 312.2 |  | 214.8 |  | 527.0 |
Olumiant® | 46.3 |  | 171.0 |  | 217.4 |  |  | 42.3 |  | 186.5 |  | 228.9 |
Other immunology | 3.8 |  | 8.8 |  | 12.5 |  |  | — |  | 22.0 |  | 22.0 |
Total immunology | 397.2 |  | 436.8 |  | 834.0 |  |  | 354.5 |  | 423.3 |  | 777.8 |
Neuroscience: |  |  |  |  |  |  |
Emgality® | 125.0 |  | 100.7 |  | 225.7 |  |  | 108.7 |  | 45.6 |  | 154.3 |
Other neuroscience | 38.2 |  | 125.2 |  | 163.4 |  |  | 35.8 |  | 170.4 |  | 206.2 |
Total neuroscience | 163.2 |  | 225.9 |  | 389.1 |  |  | 144.5 |  | 216.0 |  | 360.5 |
Other: |  |  |  |  |  |  |
Cialis® | 5.9 |  | 133.4 |  | 139.3 |  |  | 7.6 |  | 92.7 |  | 100.3 |
Forteo® | 21.7 |  | 39.5 |  | 61.3 |  |  | 70.7 |  | 51.7 |  | 122.3 |
Other | 18.1 |  | 23.3 |  | 41.3 |  |  | 30.5 |  | 22.2 |  | 52.8 |
Total other | 45.7 |  | 196.2 |  | 241.9 |  |  | 108.7 |  | 166.6 |  | 275.3 |
Revenue | $ | 5,694.4 |  | $ | 3,073.7 |  | $ | 8,768.0 |  |  | $ | 4,436.2 |  | $ | 2,523.9 |  | $ | 6,960.0 |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (2) Humalog revenue includes insulin lispro. (3) Basaglar revenue includes Rezvoglar®. The following table summarizes revenue by geographical area:
| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
Revenue(1): |  |  |  |  |  |  |
U.S. | $ | 5,694.4 |  |  | $ | 4,436.2 |  |  |  |  |
Europe | 1,440.7 |  |  | 1,090.9 |  |  |  |  |
China | 376.2 |  |  | 372.7 |  |  |  |  |
Japan | 363.9 |  |  | 387.2 |  |  |  |  |
Other foreign countries | 892.9 |  |  | 673.1 |  |  |  |  |
Revenue | $ | 8,768.0 |  |  | $ | 6,960.0 |  |  |  |  |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer or other party.
Schedule of Amounts Recorded for Contract Liabilities | The following table summarizes contract liability balances:
| March 31, 2024 |  | December 31, 2023
Contract liabilities | $ | 186.7 |  |  | $ | 193.6 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration